What is CVKD (CVKD) stock price today?

CVKD (CVKD) is currently trading at $2.06, up 0.98% today.

What is CVKD P/E ratio?

CVKD's P/E ratio is -0.78. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CVKD return on equity (ROE)?

CVKD's return on equity (ROE) is -433.33%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is CVKD's market cap?

CVKD has a market capitalization of $6.38M.

NASDAQ · Biotechnology

CVKD (CVKD) Stock

$2.06 +0.98% NASDAQ: CVKD Healthcare

Valuation

Metric	Value
Price	$2.06
Market Cap	$6.38M
P/E Ratio	-0.78
P/B Ratio	4.94
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$14.64
52-Week Low	$1.94
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-433.33%
ROA	-325.00%
ROCE	-650.00%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	2.00

Annual Financials (USD)

Metric	2022	2023	2024	2025
Revenue	$0	$0	$0	$0
Operating Profit	$-3.0M	$-8.0M	$-11.0M	$-13.0M
Net Profit	$-7.0M	$-8.0M	$-11.0M	$-13.0M
EPS	$-8.66	$-9.63	$-8.73	$-6.64
Op Margin	—	—	—	—

Balance Sheet (USD)

Metric	2022	2023	2024	2025
Total Assets	$1.0M	$9.0M	$10.0M	$4.0M
Total Liabilities	$6.0M	$1.0M	$3.0M	$2.0M
Cash	$0	$8.0M	$10.0M	$4.0M
Borrowings	$1.0M	$0	$0	$0

Latest News

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress GlobeNewswire · Jul 13, 2026 Cadrenal Therapeutics Prices Private Placement for Up to $8.8 Million MT Newswires · Jul 1, 2026 Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules GlobeNewswire · Jul 1, 2026 Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress GlobeNewswire · Jun 24, 2026 Cadrenal Therapeutics to Seek US FDA's Rare Pediatric Disease Designation for Tecarfarin to Treat Children With Kawasaki Disease MT Newswires · Jun 18, 2026

Cash Flow (USD)

Metric	2022	2023	2024	2025
Operating Cash Flow	$-1.0M	$-4.0M	$-7.0M	$-13.0M
Investing Cash Flow	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$4.0M	$-1.0M
Net Cash Flow	$0	$8.0M	$2.0M	$-6.0M
Free Cash Flow	$-1.0M	$-4.0M	$-7.0M	$-13.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-73.89%
Quick Ratio	2.68
Interest Coverage	—
Return 1Y	-80.83%
Return 3Y	-87.86%
Return 5Y	—

Ownership

Insiders Held14.84%

Institutions Held3.30%

Institutions Float Held3.88%

Institutional Holder	Shares	Report Date
Vanguard Capital Management LLC	45,201	2026-03-31
Geode Capital Management, LLC	21,626	2026-03-31
Vanguard Fiduciary Trust Co	8,311	2026-03-31
JPMORGAN CHASE & CO	7,500	2026-03-31
Blackrock Inc.	5,496	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CLGN	$0.27	-9.04%	-0.48	$3.54M	0.00%
IBIO	$1.45	+1.40%	-0.91	$22.89M	0.00%
ITRMIterum Therapeutics plc	$0.03	-10.98%	-0.06	$1.60M	0.00%
KLTOKlotho Neurosciences, Inc.	$0.38	-7.10%	-1.13	$20.08M	0.00%
NRSNNeuroSense Therapeutics Ltd.	$0.60	-0.35%	-1.35	$21.21M	0.00%

About CVKD

CVKD is led by CEO Quang X. Pham, employs 4 people, headquartered in US, publicly traded since 2023.

CVKD stock trades at $2.06 with a market capitalization of $6.38M. The stock is valued at a price-to-earnings (P/E) ratio of -0.78, price-to-book of 4.94, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.94 and $14.64, and currently trades 85.9% below its 52-week high.

On profitability, CVKD generates a return on equity (ROE) of -433.33%, return on capital employed of -650.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides